GGrantIndex
← Leaderboards

Joseph M Salvino

Drexel University

Google Scholar ↗PubMed ↗ORCID ↗
$8,384,376
Attributed
$12,381,913
Total exposure
11
Grants
7
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.9M · FY2014–25
$2M$1.5M$1M$500K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$12,381,913 · 11

By mechanism

R01$6,946,825 · 3
R44$1,611,182 · 1
P30$1,245,942 · 1
P01$1,005,624 · 1
S10$566,728 · 1
R43$449,970 · 2

Top collaborators

Others in their field

Top investigators on “Lead”

Research focus

LeadPharmaceutical PreparationsIn VivoMalignant NeoplasmsCellsDrug KineticsPropertyTumorHigh Throughput ScreeningProteinsScreeningSmall MoleculeStructure-Activity RelationshipDesignPre-ClinicalIn VitroInhibitorDrug DiscoveryBaseBiologicalMolecularLead OptimizationBiochemicalComplex

Grant awards (29)

Targeting CDK6 expression/activity in Ph+ and Ph1-like acute lymphoblastic leukemia (ALL)$631,337
R01 · FY2025 · CA
Design of the First Mdm2 Targeting PROTACs for treatment of p53 Mutant or Deficient Cancers$544,697
R01 · FY2025 · CA · contact PI
Chemical Probes and Drug Discovery$339,305
P01 · FY2025 · CA · contact PI
Molecular Screening and Protein Expression Shared Resource$223,685
P30 · FY2025 · CA · contact PI
Pilot Studies of NN-01-195, a New Tumor-Targeted AURKA Inhibitor$186,000
R03 · FY2025 · CA
Targeting CDK6 expression/activity in Ph+ and Ph1-like acute lymphoblastic leukemia (ALL)$599,770
R01 · FY2024 · CA
Design of the First Mdm2 Targeting PROTACs for treatment of p53 Mutant or Deficient Cancers$515,157
R01 · FY2024 · CA · contact PI
Chemical Probes and Drug Discovery$323,280
P01 · FY2024 · CA · contact PI
Targeting CDK6 expression/activity in Ph+ and Ph1-like acute lymphoblastic leukemia (ALL)$618,711
R01 · FY2023 · CA
Design of the First Mdm2 Targeting PROTACs for treatment of p53 Mutant or Deficient Cancers$529,097
R01 · FY2023 · CA · contact PI
Chemical Probes and Drug Discovery$343,039
P01 · FY2023 · CA · contact PI
Molecular Screening and Protein Expression Shared Resource$207,414
P30 · FY2023 · CA · contact PI
Targeting CDK6 expression/activity in Ph+ and Ph1-like acute lymphoblastic leukemia (ALL)$618,711
R01 · FY2022 · CA
Design of the First Mdm2 Targeting PROTACs for treatment of p53 Mutant or Deficient Cancers$558,144
R01 · FY2022 · CA · contact PI
Molecular Screening and Protein Expression Shared Resource$207,414
P30 · FY2022 · CA · contact PI
Targeting CDK6 expression/activity in Ph+ and Ph1-like acute lymphoblastic leukemia (ALL)$645,339
R01 · FY2021 · CA
Purchase of an Echo 650 acoustic liquid handler with Access workstation$566,728
S10 · FY2021 · OD · contact PI
Molecular Screening and Protein Expression Shared Resource$207,414
P30 · FY2021 · CA · contact PI
Molecular Screening and Protein Expression Shared Resource$192,601
P30 · FY2020 · CA · contact PI
Molecular Screening and Protein Expression Shared Resource$207,414
P30 · FY2019 · CA · contact PI
A NOVEL SMALL MOLECULE CX3CR1 ANTAGONIST HALTS METASTASIS$789,107
R44 · FY2018 · CA · contact PI
A NOVEL SMALL MOLECULE CX3CR1 ANTAGONIST HALTS METASTASIS$822,075
R44 · FY2017 · CA · contact PI
Development of a Novel Inducer for EBV Lytic Therapy$546,954
R01 · FY2017 · CA
Development of a Novel Inducer for EBV Lytic Therapy$546,954
R01 · FY2016 · CA
A Potent Small Molecule Sigma1 Modulator Degrades Androgen Receptor In Castration Resistant Prostate Cancer$225,222
R43 · FY2016 · CA
Development of a Novel Inducer for EBV Lytic Therapy$591,954
R01 · FY2015 · CA
In Vivo Study of of Chemokine Antagonists for Cancer$168,019
R21 · FY2015 · CA · contact PI
A Potent Small Molecule Chemokine Antagonist Blocks Tumor Cell Dissemination In V$224,748
R43 · FY2014 · CA · contact PI
In Vivo Study of of Chemokine Antagonists for Cancer$201,623
R21 · FY2014 · CA · contact PI